This study focuses on Diabetic Macular Edema, a condition where swelling occurs in the retina, which is the light-sensitive layer at the back of the eye. The purpose of the study is to compare the effectiveness of a new treatment called EYP-1901, a type of tyrosine kinase inhibitor, against a known medication called aflibercept. While aflibercept is administered through an intravitreal injection, which involves medicine being placed directly into the eye, EYP-1901 is provided as an implant.

Participants in the study will be assigned to receive either the test medication or the comparison medication. The process involves monitoring changes in best corrected visual acuity, which refers to how clearly a person can see when wearing glasses or contact lenses. The study will observe how these treatments affect the thickness of the retina and how frequently eye treatments are required over a set period of time.